GN11 MOUSE GNRH NEURONAL CELL LINE (C005B-315653)

General description

Access to UM-SCC-105 Cells is limited solely to those officers, employees and students of PURCHASER′s institution who need access to perform research. PURCHASER may not distribute UM-SCC-105 Cells or derivatives to third parties. PURCHASER shall comply with all applicable laws in its use and handling of the Product and shall keep it under reasonable safe and secure conditions to prevent unauthorized use or access.THIS PRODUCT IS ONLY AVAILABLE FOR SALE TO ACADEMIC INSTITUTIONS OR NOT-FOR-PROFIT ENTITIES FOR USE UNDER THIS LIMITED USE LABEL LICENSE. FOR INFORMATION ON COMMERCIAL LICENSING OF UM-SCC-105 CELLS, INCLUDING LICENSING TO COMMERCIAL ENTITIES, PLEASE CONTACT: licensing@milliporesigma.com.

Application

• Each vial contains >= 1X10⁶ viable cells.
• UM-SCC-105 cells are verified to be of human origin and negative for mouse, rat, Chinese hamster, Golden Syrian hamster, and non-human primate interspecies contamination, as assessed by a Contamination Clear panel by Charles River Animal Diagnostic Services
• Cells tested negative for infectious diseases against a Human Essential CLEAR panel by Charles River Animal Diagnostic Services (Cells are HPV18-Positive.)
• Cells tested negative for mycoplasma.

Features and Benefits

The HPV18-positive SCC-105 squamous cell carcinoma cell line was derived from the laryngeal tumor of a 51yo never-smoker male and is a suitable in vitro model of H&N carcinoma studies.

Target description

HPV-related head and neck cancers are often more responsive with current therapeutic protocols when compared to HPV-negative tumors that are derived from the same anatomical location. This has propagated interest in reducing the intensity levels of treatment. However, even when combining strong therapeutic approaches with chemotherapy, 20-30% of HPV-positive cancers progress and no longer respond to treatment methods. This makes it continually important to understand why certain tumors progress while others appropriately respond to treatment. ​​The UM-SCC-105 cell line is HPV18-positive. This cell line was biopsied from a laryngeal tumor of a 51-year-old never-smoker male individual. It is understood that the cancer progression was driven by E6/E7 viral mechanisms rather than cell cycle mutations typically related to tobacco smoke carcinogenesis, giving this cell line a unique background. Other mechanisms, such as understanding viral integration into the host genome, continue to be an important aspect of understanding HPV-driven cancers. The UM-SCC-105 cell line positively expresses head and neck cancer markers such as ALDH1, CD44, and ABCG2. ALDH1 and CD44 have both been implicated as cancer stem cell (CSC) markers in head and neck cancers. CSCs are often associated with a poor prognosis and are necessary to understanding aggressive tumor behavior that overcomes treatment. ABCG2 is also addressed as a common head and neck squamous cell carcinoma marker. ABCG2 functions as an efflux pump and is associated with anticancer drug resistance. Source: The UM-SCC-105 cell line is derived from a biopsied laryngeal tumor of a 51-year-old “never smoker” male.​References: 1. Front Oncol. (2021); 11: 606010.2. Head Neck (2016); 38(Suppl 1): E459-E467. 3. Head Neck (2017); 39(5): 840-852.4. Exp Ther Med (2011); 2(6): 1151-1157.

Storage and Stability

UM-SCC-105 cells should be stored in liquid nitrogen until use. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.